Asset Details
Do you wish to reserve the book?
Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
Do you wish to request the book?
Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
2020
Overview
Background
Breast cancer (BC) is a disease with variable morphology, clinical behaviour and response to therapy. Identifying factors associated with the progression of early-stage BC can help understand the risk of metastasis and guide treatment decisions. Myxovirus resistance 1 (MX1), which is involved in the cellular antiviral mechanism, plays a role in some solid tumours; however, its role in invasive BC remains unknown. In this study, we aimed to explore the clinicopathological and prognostic significance of MX1 in BC.
Methods
MX1 was assessed at the protein level using tissue microarrays from a large well-annotated BC cohort (
n
= 845). The expression of
MX1
mRNA was assessed at the transcriptomic level using the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC;
n
= 1980) and validated using three publicly available cohorts on Breast Cancer Gene-Expression Miner (bc-GenExMiner version 4.4). The associations between MX1 expression and clinicopathological factors, and outcome were evaluated.
Results
High MX1 protein expression was associated with features of aggressiveness, including large tumour size, high tumour grade, high Nottingham prognostic index scores, hormone receptor negativity and high Ki67 expression. High MX1 expression showed an association with poor patient outcome and it was an independent predictor of short BC-specific survival (
p
= 0.028; HR = 1.5; 95% CI = 1.0–2.2). Consistent with the protein results, high
MX1
mRNA levels showed an association with features of aggressive behaviour and with shorter survival.
Conclusion
This study identified MX1 as an independent predictor of poor outcome in patients with BC. Further functional studies are needed to investigate the biological role of MX1 in BC and its potential value as a therapeutic target.
Publisher
Springer US,Springer,Springer Nature B.V
Subject
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ B cells
/ Biomarkers, Tumor - genetics
/ Biomarkers, Tumor - metabolism
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - metabolism
/ Breast Neoplasms - pathology
/ Female
/ Gene Expression Regulation, Neoplastic
/ Humans
/ Medicine
/ Myxovirus resistance proteins
/ Myxovirus Resistance Proteins - genetics
/ Myxovirus Resistance Proteins - metabolism
/ Oncology
/ Patients
/ Proteins
/ Receptor, ErbB-2 - metabolism
/ Receptors, Estrogen - metabolism
/ Receptors, Progesterone - metabolism
/ RNA
